Advances in animal models of prenatal opioid exposure

Trends Neurosci. 2024 Apr 12:S0166-2236(24)00042-0. doi: 10.1016/j.tins.2024.03.005. Online ahead of print.ABSTRACTNeonatal opioid withdrawal syndrome (NOWS) is a growing public health concern. The complexity of in utero opioid exposure in clinical studies makes it difficult to investigate underlying mechanisms that could ultimately inform early diagnosis and treatments. Clinical studies are unable to dissociate the influence of maternal polypharmacy or the environment from direct effects of in utero opioid exposure, highlighting the need for effective animal models. Early animal models of prenatal opioid exposure primarily used the prototypical opioid, morphine, and opioid exposure that was often limited to a narrow period during gestation. In recent years, the number of preclinical studies has grown rapidly. Newer models utilize both prescription and nonprescription opioids and vary the onset and duration of opioid exposure. In this review, we summarize novel prenatal opioid exposure models developed in recent years and attempt to reconcile results between studies while critically identifying gaps within the current literature.PMID:38614891 | DOI:10.1016/j.tins.2024.03.005
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research